Navigation Links
Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Date:2/4/2009

JERUSALEM, Israel, February 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, announced today that it has concluded a proof of concept study in South Africa of insulin suppositories, ORMD-0802, using its proprietary technology. Eight healthy volunteers came for two visits, with two different formulations.

The insulin suppositories showed rapid insulin absorption and reactive glucose lowering effect. The suppositories were well tolerated and no adverse events were encountered.

Oramed's insulin suppositories are advanced as a treatment alternative for injectable insulin. Such an alternative may be especially useful for individuals with immunological-based reactions to repeated injections and who require a temporary recess from daily injections.

Suppositories are often used in pediatrics for the treatment of conditions such as nausea and vomiting, sedation, analgesia, control of seizures, or antipyresis. Suppositories also provide rapid absorption and have the advantage of being relatively painless.

"This proof of concept study of ORMD-0802, insulin suppository, was an important milestone in using our proprietary technology to expand our product pipeline," said Oramed's CEO, Nadav Kidron.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information,
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
2. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
3. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
4. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
5. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
6. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 A ... of the organ protrudes through the wall of a weak ... area at birth are some of the causes of hernias. ... hiatal, femoral, and incisional. An inguinal hernia is when part ... umbilical hernia is found in the area of the umbilicus. ...
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... The medical magnetic resonance imaging (MRI) ... with world market revenues for 2013 at $5.1 ... types of medical imaging have led to improvements ... conditions in children and adults, each imaging procedure ... Medical Imaging Markets , analyzes the current and ...
Breaking Medicine Technology:Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Meeting of the Heart Failure Society of America (HFSA) will ... recent studies relating to heart failure. Dr. D.J. ... a recent study of heart failure patients who are hospitalized ... the heart, and the heart is unable to manage the ...
... the following update for its range of advanced wound care ... regulatory approvals and product listings, Innocoll has added six more ... and spray formats that are available for commercialization in the ... Zealand. These products include:   CollaCare®, a ...
Cached Medicine Technology:Studying Fluid Overflow in Patients With Devices 2Studying Fluid Overflow in Patients With Devices 3Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products 2
(Date:11/28/2014)... Melbourne, Australia (PRWEB) November 28, 2014 ... has undergone healthy growth over the past five ... population's increasing acceptance of therapies that are either ... conventional treatments. According to IBISWorld industry analyst David ... the ageing population and growing private health insurance ...
(Date:11/28/2014)... Kramer HealthDay Reporter , THURSDAY, ... the kitchen, through cooking classes or at home, may make ... recent review. Cooking programs and classes for children seem ... the new research. And, although the review didn,t look at ... programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... November 28, 2014 Mabel’s Labels ... kids lose® and an award-winning company established by four ... Cynthia Esp, and Tricia Mumby have been honored with ... recognized with the PROFIT Award for Excellence in Entrepreneurship. ... Esp, and Tricia Mumby) accepted the award on behalf ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Patten Pecans, ... locally grown. With those passions driving them, they've added ... Grown. Having tried other pecans oils, they've found this ... Georgia to be exceptionally flavorful, retaining the buttery pecan ... same nutritional benefits found in pecans nuts ...
(Date:11/28/2014)... Brentwood, TN (PRWEB) November 28, 2014 ... in Tennessee for the first time. PAI Medical Group ... M.D. will be performing a robotic hair transplant procedure ... at 9:00 A.M. , The first in Tennessee and ... PAI Medical Group now offers ARTAS robotic hair transplantation. ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2
... from more emotional and behavioral difficulties when compared to ... the most when a parent is deployed overseas, according ... that having a parent deployed for a longer period ... struggled with emotional problems were important factors associated with ...
... , NEW ORLEANS and SUNNYVALE, Calif., Dec. ... interim results from a Phase I/II study showing safety and ... (NHL) treated with its HDAC inhibitor PCI-24781 as a single ... Annual Meeting being held in New Orleans, LA (Abstract # ...
... growth factor, researchers say , SUNDAY, Dec. 6 (HealthDay ... main tumor to other parts of the body is controlled ... a promising target for new drugs to prevent metastatic breast ... TGFb (transforming growth factor beta) regulates normal cell growth and ...
... NEW ORLEANS, Dec. 6 Sickle cell disease, a condition ... of the most common genetic blood disorders affecting millions of ... presented today at the 51st Annual Meeting of the American ... that the H1N1 pandemic presents for children with this blood ...
... ... Greater VA Healthcare System in West Los Angeles, will once again create a holiday party. ... and their families. , ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the community, in cooperation ...
... 5 , What: Cuts for a Cause ... fight against cancer and other terminal illnesses affecting children. All proceeds ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... Falls Church for all guests. Hoa Lai, a DJ known for ...
Cached Medicine News:Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
... fixation device offers superior fixation strength ... firmly reattaches soft tissue to the ... is indicated for the fixation of ... bone. The implant is composed of ...
... simple to use system can be used ... and is pre-packaged on a sterile disposable ... a simple and reproducible insertion of the ... Sliding (I.S.S.™) Eyelet Design allows for the ...
... is the smallest, strongest anchor on ... placement into even the smallest bones. ... or 4-0 ETHIBOND EXCEL suture with ... swaged needles. The kit includes a ...
Medicine Products: